Saxenda in Obesity Services (STRIVE Study)

NCT03036800 · Completed

Last updated 2026-05-28

This clinical trial is testing the effectiveness of the medication Saxenda in helping adults with obesity or diabetes lose at least 15% of their body weight.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 392 people

Who can join Ages 18–75 · all sexes

Timeline Started 2017-11 · est. completion 2022-02

Where 5 sites · Ireland, United Kingdom

What this study is testing ClinicalTrials.gov NCT03036800 ↗

Description as written by the study sponsor.

A two year, parallel, two group, open-label, real-world randomised controlled trial (RCT) design for subjects with severe and complex obesity who are referred to a Tier 3 or equivalent specialist weight management/obesity service. Participants will be randomised to receive 1) standard care (obesity-specialist care), or 2) targeted prescribing pathway (obesity-specialist care plus targeted use of Liraglutide 3.0mg \[LIRA 3mg\] with pre-specified stopping rules for the medication). The aim of the study is to compare the effectiveness, budget impact, and cost-effectiveness between the two groups in a real-world setting among otherwise largely unselected patients.

Treatments tested

Saxenda also known as Liraglutide 3mg Drug

standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
Specialist Obesity Management Services Other

Specialist Obesity Management Services standard of care

Main thing measured	Weight Loss of ≥15% From Baseline (Complete Cases)
Sponsor	University of Leicester
Conditions studied	Obesity, Weight Loss, Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03036800 ↗